Company intelligence / Profile preview

VesiCURE Therapeutics

Suzhou（Suzhou Industrial Park）, Jiangsu Province, Chinavesicure.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

VesiCURE has developed a proprietary exosome-based drug delivery platform ("modEXO") to enable targeted therapies for oncology and inflammatory/immune conditions. The company’s pipeline includes multiple preclinical-stage assets targeting cancers such as lung cancer, solid tumors, liver disease, and immune/inflammatory disorders. No clinical results have been reported yet.

Therapeutic areas: ImmunologyOncologyPulmonologyGastroenterology
Modalities: Exosomes / extracellular vesicles (EVs)siRNA / nucleic acidsOligonucleotidesTherapeutic vaccines
Industry: Biotech

Drug pipeline

4 assets

MDX-102

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on VesiCURE Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VesiCURE Therapeutics.

Explore the full profile